SAN FRANCISCO--(BUSINESS WIRE)--Jaguar Health, Inc. (NASDAQ: JAGX) (Jaguar), a natural-products pharmaceuticals company focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis, announced today that The American Association of Veterinary State Boards (AAVSB) Registry of Approved Continuing Education (RACE) committee has reviewed and approved Jaguar’s “Diarrhea in Foals” continuing education (CE) program as meeting the standards adopted by the AAVSB.
The AAVSB is a non-profit organization whose mission is to support and advance the regulatory process for veterinary medicine. The membership of the AAVSB consists of 62 jurisdictions representing all U.S. states and the District of Columbia, Puerto Rico, the U.S. Virgin Islands, and nine Canadian provinces: Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Ontario, Prince Edward Island, and Saskatchewan.
The purpose of the RACE program is to develop and apply uniform standards related to CE providers and programs in veterinary medicine, and ensuring that all RACE-approved CE programs meet appropriate standards of quality. Jaguar’s “Diarrhea in Foals” program has been approved by the AAVSB RACE committee to offer a total of 1.50 CE credits to each participating veterinarian or veterinary technician. The program may be repeated by Jaguar within the two-year program approval period at different locations and/or on different dates, with advance notice to AAVSB.
Most state veterinary boards require veterinarians and credentialed veterinary technicians to accumulate CE credits every 1–2 years. Although veterinary CE standards are not uniform among U.S. state veterinary boards, RACE-approved CE is recognized by most AAVSB member boards.
“Participation in CE programs helps veterinarians and veterinary technicians remain apprised of current and cutting-edge veterinary care,” commented equine medical consultant Dr. Siobhan McAuliffe, MVB, DACVIM, “and helping veterinary professionals expand their clinical knowledge and learn about new technology helps them take better care of their patients.”
Dr. McAuliffe served as the primary investigator for clinical studies conducted in 2015 for Neonorm™ Foal, Jaguar’s plant-based anti-diarrheal product for newborn horses.
About Jaguar Health, Inc.
Jaguar Health, Inc. is a natural-products pharmaceuticals company focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis. Our wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Our Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Mytesi® is in development for multiple possible follow-on indications, including cancer therapy-related diarrhea; orphan-drug indications for infants and children with congenital diarrheal disorders and short bowel syndrome; supportive care for inflammatory bowel disease (IBD); irritable bowel syndrome (IBS); and as a second-generation anti-secretory agent for use in cholera patients. Canalevia™ is our lead animal prescription drug candidate, intended for treatment of various forms of diarrhea in dogs. Equilevia™ is Jaguar’s non-prescription product for total gut health in equine athletes. Canalevia™ and Equilevia™ contain ingredients isolated and purified from the Croton lechleri tree, which is sustainably harvested. Neonorm™ Calf and Neonorm™ Foal are Jaguar’s lead non-prescription animal products. Mytesi®, Canalevia™, Equilevia™ and Neonorm™ are distinct products that act at the same last step in a physiological pathway generally present in mammals.
For more information about Jaguar, please visit jaguar.health. For more information about Napo, visit napopharma.com.
Forward-Looking Statements
Certain statements in this press release constitute “forward-looking statements.” These include statements regarding planned, potential follow-on indications for Mytesi®. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Jaguar-JAGX
